Member Spotlight: Biocon Biologics
Investment, Innovation, Growth and Affordability Biocon Biologics has emerged as a leading biosimilars player in the U.S. and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a fully integrated biosimilar company, it is singularly focused on the development, manufacturing, distribution, and commercialization of the highest quality biosimilars in […]
Pharmacy Benefit Managers Are Blocking Patient Access to Biosimilar Insulin
Blog originally released by the Biosimilars Council Just two weeks ago, the U.S. biosimilars industry entered a new phase when eight biosimilar versions of Humira launched with prices reaching as low as 85 percent below the brand list price. Humira is the bestselling drug in the U.S., and new biosimilar competition represents a major expansion […]
AAM’s Erica Klinger speaks with Connor Nell and Brian Biehn from AmerisourceBergen #GBW2022
It’s the third-annual Global Biosimilars Week, a social media campaign created and driven by the International Generic and Biosimilar Medicines Association (IGBA) and its members to raise awareness about biosimilar medicines. In conjunction with this weeklong campaign, Erica Klinger, Senior Director of Marketing at the Association for Accessible Medicines (AAM) and Chair of the 2022 […]
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
In 2021, employers experienced a 6.3% jump in health benefit costs.1 Findings such as these, paired with high brand-name drug costs, are why commercial and employer-sponsored health plans have long looked forward to savings from biosimilar competition. Unfortunately, employers soon will be facing higher costs, if provisions in the Build Back Better Act (BBB) that […]
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines. According to IQVIA, savings from biosimilars increased over 800% from 2018 to 2020, from under $900M in 2018 to $7.9B in 20201,2. This is the result of new biosimilar launches and robust competition under which […]
Everything You Need to Know About Biosimilars – All in One Place
Originally published on the Biosimilars Council. Biosimilar medicines are revolutionary therapeutics that treat patients at a fraction of the cost of brand-name biologics. However, public awareness and trust of biosimilars is still evolving, meaning many patients and providers are overpaying for expensive brand-name biologics. To address this education gap, the Biosimilars Council launched a new, […]
HHS Finds Biosimilars Use Results in “Significant Spending Reduction” For Medicare and Its Beneficiaries
WASHINGTON D.C. (April 1, 2022) – A new study from HHS’ Office of the Inspector General (OIG) finds increasing biosimilars use would result in “significant spending reduction” for Medicare Part D and its beneficiaries. According to OIG, greater biosimilar use between 2015 and 2019 could have saved seniors 12-22% and reduced Medicare spending by 18-31%, […]
As Health Care Spending in US Projected to Increase, Generics and Biosimilars Expected to Moderate Growth
Recently, the Centers for Medicare & Medicaid Services (CMS) released the 2021-2030 National Health Expenditure (NHE) report, prepared by their Office of the Actuary. The report serves as the authoritative estimate of total U.S. health spending and provides important clues as to what is (and is not) driving health care costs.1 CMS found that national […]
Biosimilars Council — Leading on Biosimilars for America’s Patients
The Biosimilars Council, a division of the Association for Accessible Medicines, works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, […]
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
This week, we learned that employers experienced a 6.3% jump in health benefit costs last year.1 Findings such as these, paired with high brand-name drug costs, are why commercial and employer-sponsored health plans have long looked forward to savings from biosimilar competition. Unfortunately, employers soon will be facing higher costs, if provisions in the Build […]
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines. According to recent data from IQVIA, savings from biosimilars increased over 800% from 2018 to 2020, from under $900M in 2018 to $7.9B in 20201. These savings are projected to reach over $30B annually by […]
Biosimilars Council Encourages Stakeholders, Advocates to Join #GlobalBiosimilarsWeek
WASHINGTON, D.C. (November 1, 2021) – AAM’s Biosimilars Council, in accordance with the International Generic and Biosimilar Medicines Association (IGBA), invites all biosimilars advocates and stakeholders to take part in the second annual Global Biosimilars Week on November 1st–5th. This social media awareness campaign will gather biosimilar resources, ideas, and stories from around the world […]
